Chimeric Therapeutics (ASX:CHM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Chimeric Therapeutics (ASX:CHM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Final Director's Interest Notice
Board Update
Application for quotation of securities - CHM
Appointment of Financial Adviser for Strategic Review
Chimeric Therapeutics appoints independent adviser for strategic review to maximize shareholder value
Application for quotation of securities - CHM
Application for quotation of securities - CHM
CHM announces positive Phase 1/2 data at ASCO
Chimeric Therapeutics reports positive Phase 1/2 data for CHM CDH17 CAR-T in GI cancers
Application for quotation of securities - CHM
Notice under section 708A
Application for quotation of securities - CHM
Application for quotation of securities - CHM
Proposed issue of securities - CHM
Notification of cessation of securities - CHM
Change in substantial holding
Notification regarding unquoted securities - CHM
Notice under section 708A
Application for quotation of securities - CHM
Application for quotation of securities - CHM
Notification regarding unquoted securities - CHM
Notification regarding unquoted securities - CHM
Quarterly Activities/Appendix 4C Cash Flow Report
Chimeric Therapeutics advances clinical trials, refreshes board, and manages funding amid cash outflows
Capital Consolidation Complete
Update - Consolidation/Split - CHM
CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi
Chimeric Therapeutics reports 60% complete response in Phase 1B AML trial with CHM CORE-NK
Update - Consolidation/Split - CHM
Results of Meeting